Exploring the Anti-Hypoxaemia Effect of Hydromethylthionine: A Prospective Study of Phase 3 Clinical Trial Participants
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241813747 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Mohammad Arastoo und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB25 2ZP, UK. Hauptthemen laut MEDLINE: Methylene Blue, COVID-19. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: TauRx Therapeutics Ltd., Singapore.
Abstract (Originalsprache)
Methylthioninium chloride (MTC) is a standard treatment for methaemoglobinaemia. A preparation of reduced MTC has been reported to increase blood oxygen saturation (SpO2) and lower respiratory rates in patients with severe COVID-19. We have developed a stable form of reduced methylthionine (hydromethylthionine-mesylate, HMTM) having a benign safety profile in two Phase 3 trials in Alzheimer’s disease. The aim of this prospective study was to determine the effects of oral HMTM on SpO2 and methaemoglobin (metHb) levels in a cohort of patients with mild hypoxaemia not due to COVID-19. Eighteen participants randomised to a single dose of 4, 75, 100 or 125 mg doses of HMTM had SpO2 levels below 94% at baseline. Patients were routinely monitored by pulse oximetry after 4 h, and after 2 and 6 weeks of twice daily dosing. Significant ~3% increases in SpO2 occurred within 4 h and were sustained over 2 and 6 weeks with no dose differences. There were small dose-dependent increases (0.060–0.162%) in metHb levels over 2 to 6 weeks. Minimum-energy computational chemistry revealed that HMT can bind within 2.10 Å of heme iron by donating a pair of electrons from the central nitrogen of HMT to d orbitals of heme iron, but with lower affinity than oxygen. In conclusion, HMTM can increase SpO2 without reducing metHb by acting as a strong displaceable field ligand for heme iron. We hypothesise that this facilitates a transition from the low oxygen affinity T-state of heme to the higher affinity R-state. HMTM has potential as an adjunctive treatment for hypoxaemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB25 2ZP, UK.
- Scottish Biologics Facility, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB25 2ZP, UK.
- NovaData Solutions Ltd., 15 Monreith Rd, Newlands, Glasgow G43 2NX, UK.
- Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, UK.
- TauRx Therapeutics Ltd., 395 King Street, Aberdeen AB24 3FX, UK.
- Syneos Health, LLC, Morrisville, NC 27560, USA.
ORCID-Profile: Claire Hull, Keith Robinson, Charles R Harrington
Förderung
- TauRx Therapeutics Ltd., Singapore
Zitieren
APA
Arastoo, M., Mazanetz, M. P., Miller, S., Shiells, H., Hull, C., Robinson, K., Storey, J. M. D., Harrington, C. R., & Wischik, C. M. (2023). Exploring the Anti-Hypoxaemia Effect of Hydromethylthionine: A Prospective Study of Phase 3 Clinical Trial Participants. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241813747
Vancouver
Arastoo M, Mazanetz MP, Miller S, Shiells H, Hull C, Robinson K, et al. Exploring the Anti-Hypoxaemia Effect of Hydromethylthionine: A Prospective Study of Phase 3 Clinical Trial Participants. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241813747
BibTeX
@article{Arastoo2023,
author = {Arastoo, Mohammad and Mazanetz, Michael P and Miller, Sonya and Shiells, Helen and Hull, Claire and Robinson, Keith and Storey, John M D and Harrington, Charles R and Wischik, Claude M},
title = {Exploring the Anti-Hypoxaemia Effect of Hydromethylthionine: A Prospective Study of Phase 3 Clinical Trial Participants},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241813747}
}
EUVIMED